The treatment of patients with HIV
- PMID:20703338
- PMCID: PMC2915483
- DOI: 10.3238/arztebl.2010.0507
The treatment of patients with HIV
Abstract
Background: Infection with the human immunodeficiency virus (HIV) remains a major medical challenge.
Methods: Selective literature review, including the current German/Austrian, European, and American guidelines on the treatment of HIV infection in adults.
Results: In Germany, 3000 persons become infected with HIV each year; in 2009, 67,000 persons in Germany were living with HIV. When highly active antiretroviral therapy (HAART) is initiated in time, patients can achieve a nearly normal life expectancy. Nonetheless, in Germany as elsewhere, 30% of patients receive the diagnosis of HIV infection only when they have reached the AIDS stage of the disease or are suffering from advanced immunodeficiency. HAART should be started, at the latest, when the CD4-positive helper cell count drops below 350/microL. Primary drug resistances, accompanying illnesses, and the patient's living circumstances must all be taken into account in the selection of antiretroviral drugs. The goal of treatment is lasting suppression of HIV-RNA to below 50 copies per milliliter of plasma.
Conclusions: HIV testing should be offered to all patients at high risk for HIV infection and all persons newly diagnosed with a sexually transmitted disease. As persons with HIV grow older, their treatment is complicated by increasing comorbidity and requires increased vigilance for possible drug interactions.
Figures
Similar articles
- [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].Panel de expertos de Gesida y Plan Nacional sobre el Sida.Panel de expertos de Gesida y Plan Nacional sobre el Sida.Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26.Enferm Infecc Microbiol Clin. 2009.PMID:19246124Spanish.
- [Clinical management of acute and chronic human immunodeficiency virus infection before starting antiretroviral treatment].Miró JM, Manzardo C, Zamora L, Pumarola T, Herreras Z, Gallart T, Gatell JM.Miró JM, et al.Enferm Infecc Microbiol Clin. 2011 Dec;29(10):759-72. doi: 10.1016/j.eimc.2011.10.009. Epub 2011 Nov 10.Enferm Infecc Microbiol Clin. 2011.PMID:22078726Review.Spanish.
- Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A.Jacobson LP, et al.Am J Epidemiol. 2002 Apr 15;155(8):760-70. doi: 10.1093/aje/155.8.760.Am J Epidemiol. 2002.PMID:11943695
- Dynamics of T-cell subsets and their relationship with oral and systemic opportunistic infections in HIV/AIDS patients during the first year of HAART in Guangxi, China.Zhang L, Huang Y, Liu Z, Liu W, Qin Q, Tao R.Zhang L, et al.J Med Virol. 2015 Jul;87(7):1158-67. doi: 10.1002/jmv.24177. Epub 2015 Mar 16.J Med Virol. 2015.PMID:25777553
- AIDS-related opportunistic illnesses and early initiation of HIV care remain critical in the contemporary HAART era: a retrospective cohort study in Taiwan.Lee CY, Tseng YT, Lin WR, Chen YH, Tsai JJ, Wang WH, Lu PL, Tsai HC.Lee CY, et al.BMC Infect Dis. 2018 Jul 28;18(1):352. doi: 10.1186/s12879-018-3251-1.BMC Infect Dis. 2018.PMID:30055564Free PMC article.
Cited by
- 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.Calvet CM, Choi JY, Thomas D, Suzuki B, Hirata K, Lostracco-Johnson S, de Mesquita LB, Nogueira A, Meuser-Batista M, Silva TA, Siqueira-Neto JL, Roush WR, de Souza Pereira MC, McKerrow JH, Podust LM.Calvet CM, et al.PLoS Negl Trop Dis. 2017 Dec 27;11(12):e0006132. doi: 10.1371/journal.pntd.0006132. eCollection 2017 Dec.PLoS Negl Trop Dis. 2017.PMID:29281643Free PMC article.
- Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia.Naeth G, Ehret R, Wiesmann F, Braun P, Knechten H, Berger A.Naeth G, et al.Med Microbiol Immunol. 2013 Feb;202(1):67-75. doi: 10.1007/s00430-012-0249-y. Epub 2012 Jun 15.Med Microbiol Immunol. 2013.PMID:22699843
- How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health.Kuznetsov V, Lee HK, Maurer-Stroh S, Molnár MJ, Pongor S, Eisenhaber B, Eisenhaber F.Kuznetsov V, et al.Health Inf Sci Syst. 2013 Jan 10;1:2. doi: 10.1186/2047-2501-1-2. eCollection 2013.Health Inf Sci Syst. 2013.PMID:25825654Free PMC article.Review.
- A Review on the Present Advances on Studies of Toxoplasmosis in Eastern Africa.Mose JM, Kagira JM, Kamau DM, Maina NW, Ngotho M, Karanja SM.Mose JM, et al.Biomed Res Int. 2020 Jul 6;2020:7135268. doi: 10.1155/2020/7135268. eCollection 2020.Biomed Res Int. 2020.PMID:32724808Free PMC article.Review.
- The effects of setarud on the immunological status of HIV-positive patients: Efficacy of a novel multi-herbal drug.Gholamzadeh Baeis M, Amiri G, Miladinia M.Gholamzadeh Baeis M, et al.Avicenna J Phytomed. 2017 May-Jun;7(3):232-241.Avicenna J Phytomed. 2017.PMID:28748170Free PMC article.
References
- Marcus U. Fachgruppe 34 für HIV/AIDS u. a. sexuell oder durch Blut übertragbare Infektionen: Zum Verlauf der HIV-Epidemie in Deutschland bis Ende 2009. Epidemiologisches Bulletin. 2009;(48):491–498.
- van Sighem A, Gras L, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS May 12. 2010;24(10):1527–1535. - PubMed
- Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921–929. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials